The Victoza approval comes after a priority review by the FDA, and shortly after Novo Nordisk reported the results of the phase 3 ELLIPSE trial which showed the drug was able to reduce haemoglobin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback